FMA
ANIP icon

FNY Managed Accounts’s ANI Pharmaceuticals ANIP Stock Holding History

FNY Managed Accounts’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,506
Closed -$84.1K – 429
2016
Q2 		$84.1K Buy
+1,506
New +$73.2K 0.08% 104

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

FNY Managed Accounts's ANIP Position: Q3 2016 in Review

FNY Managed Accounts sold out of ANI Pharmaceuticals (ANIP) in Q3 2016, closing a stake of 1,506 shares — an estimated $84.1K sold.

FNY Managed Accounts first reported a position in ANIP in Q2 2016 and held it in 1 quarter. The position peaked at $84.1K in Q2 2016. 171 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

  • FNY Managed Accounts reported no remaining ANI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 1,506 ANI Pharmaceuticals shares in Q3 2016, an estimated $84.1K.
  • FNY Managed Accounts first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • FNY Managed Accounts's ANI Pharmaceuticals position peaked at $84.1K in Q2 2016.
  • 171 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on FNY Managed Accounts's 13F filing for Q3 2016, filed 18 Oct 2016.